Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison.

Loke YK, Pradhan S, Yeong JK, Kwok CS.

Br J Clin Pharmacol. 2014 Oct;78(4):707-17. doi: 10.1111/bcp.12376.

2.

Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.

Skjøth F, Larsen TB, Rasmussen LH, Lip GY.

Thromb Haemost. 2014 May 5;111(5):981-8. doi: 10.1160/TH14-02-0118. Epub 2014 Feb 28.

PMID:
24577485
3.

An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.

Mantha S, Ansell J.

Thromb Haemost. 2012 Sep;108(3):476-84. doi: 10.1160/TH12-02-0093. Epub 2012 Jun 28. Review.

PMID:
22740145
4.

Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials.

Sardar P, Chatterjee S, Lavie CJ, Giri JS, Ghosh J, Mukherjee D, Lip GY.

Int J Cardiol. 2015 Jan 20;179:279-87. doi: 10.1016/j.ijcard.2014.11.101. Epub 2014 Nov 13.

PMID:
25464465
5.

Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.

Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J.

Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):480-6. doi: 10.1161/CIRCOUTCOMES.112.965988. Epub 2012 Jul 10.

6.

Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.

Alotaibi G, Alsaleh K, Wu C, Mcmurtry MS.

Int Angiol. 2014 Aug;33(4):301-8. Review.

PMID:
25056161
7.

Cardiovascular safety of new oral anticoagulants: re-analysis of 27 randomized trials based on Bayesian network meta-analysis.

Messori A.

Br J Clin Pharmacol. 2015 Jul;80(1):168-9. doi: 10.1111/bcp.12592. Epub 2015 Jun 3. No abstract available.

8.

Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.

Lip GY, Larsen TB, Skjøth F, Rasmussen LH.

J Am Coll Cardiol. 2012 Aug 21;60(8):738-46. doi: 10.1016/j.jacc.2012.03.019. Epub 2012 May 9.

9.

Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.

[No authors listed]

Prescrire Int. 2013 Jun;22(139):155-9. Review.

PMID:
23866358
10.

Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.

Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C.

Int Angiol. 2012 Aug;31(4):330-9. Review.

PMID:
22801398
11.

Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis.

Rasmussen LH, Larsen TB, Graungaard T, Skjøth F, Lip GY.

BMJ. 2012 Nov 5;345:e7097. doi: 10.1136/bmj.e7097.

12.

Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.

Cheng JW, Barillari G.

J Clin Pharm Ther. 2014 Apr;39(2):118-35. doi: 10.1111/jcpt.12122. Epub 2014 Jan 3. Review.

PMID:
24383983
13.

Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.

Loke YK, Kwok CS.

J Clin Pharm Ther. 2011 Feb;36(1):111-24. doi: 10.1111/j.1365-2710.2010.01162.x. Review.

PMID:
21198726
14.

Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.

Gómez-Outes A, Terleira-Fernández AI, Lecumberri R, Suárez-Gea ML, Vargas-Castrillón E.

Thromb Res. 2014 Oct;134(4):774-82. doi: 10.1016/j.thromres.2014.06.020. Epub 2014 Jul 6. Review.

PMID:
25037495
15.

The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis.

Cohen A, Drost P, Marchant N, Mitchell S, Orme M, Rublee D, Simon TA, Sutton A.

Clin Appl Thromb Hemost. 2012 Nov;18(6):611-27. doi: 10.1177/1076029612437579. Epub 2012 Mar 2. Review.

PMID:
22387582
16.
17.

Risk of gastrointestinal bleeding with dabigatran: a head-to-head comparative study with rivaroxaban.

Sherid M, Sifuentes H, Sulaiman S, Samo S, Husein H, Tupper R, Thiruvaiyaru D, Spurr C, Sridhar S.

Digestion. 2014;90(2):137-46. doi: 10.1159/000365967. Epub 2014 Oct 1.

PMID:
25278002
18.

Emergency surgery and trauma in patients treated with the new oral anticoagulants: dabigatran, rivaroxaban, and apixaban.

Moorman ML, Nash JE, Stabi KL.

J Trauma Acute Care Surg. 2014 Sep;77(3):486-94; quiz 486-94. doi: 10.1097/TA.0000000000000360. Review. No abstract available.

PMID:
25159255
19.

Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.

Cuker A, Siegal DM, Crowther MA, Garcia DA.

J Am Coll Cardiol. 2014 Sep 16;64(11):1128-39. doi: 10.1016/j.jacc.2014.05.065. Review.

20.

[Rivaroxaban, dabigatran and apixaban: new anticoagulants in operative urology].

John A, Michel MS.

Urologe A. 2014 Jun;53(6):893-902; quiz 903. doi: 10.1007/s00120-014-3505-5. German.

PMID:
24845012

Supplemental Content

Support Center